The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury

BACKGROUND: Cerebral oedema is associated with significant neurological damage in patients with traumatic brain injury. Bradykinin is an inflammatory mediator that may contribute to cerebral oedema by increasing the permeability of the blood-brain barrier. We evaluated the safety and effectiveness o...

Descripción completa

Detalles Bibliográficos
Autores principales: Shakur, Haleema, Andrews, Peter, Asser, Toomas, Balica, Laura, Boeriu, Cristian, Quintero, Juan Diego Ciro, Dewan, Yashbir, Druwé, Patrick, Fletcher, Olivia, Frost, Chris, Hartzenberg, Bennie, Mantilla, Jorge Mejia, Murillo-Cabezas, Francisco, Pachl, Jan, Ravi, Ramalingam R, Rätsep, Indrek, Sampaio, Cristina, Singh, Manmohan, Svoboda, Petr, Roberts, Ian
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2794266/
https://www.ncbi.nlm.nih.gov/pubmed/19958521
http://dx.doi.org/10.1186/1745-6215-10-109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2794266/
https://www.ncbi.nlm.nih.gov/pubmed/19958521
http://dx.doi.org/10.1186/1745-6215-10-109

Ejemplares similares